Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or recurrent cancer of the cervix.

Study summary:

OBJECTIVES: - Determine the antitumor activity of gemcitabine in patients with persistent or recurrent nonsquamous cell carcinoma of the cervix who failed higher priority treatment protocols. - Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive gemcitabine IV over 30 minutes weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 15-37 patients will be accrued for this study within 1 year.


DISEASE CHARACTERISTICS: - Diagnosis of persistent or recurrent nonsquamous cell carcinoma of the cervix that has failed local therapeutic measures and is considered incurable - Eligible subtypes: - Adenocarcinoma - Adenosquamous carcinoma - Undifferentiated carcinoma - Must have documented disease progression - Histologic confirmation of original primary tumor required - Bidimensionally measurable disease - Ineligible for higher priority GOG protocol PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - GOG 0-2 Life expectancy: - Not specified Hematopoietic: - Platelet count at least 100,000/mm^3 - Granulocyte count at least 1,500/mm^3 Hepatic: - Bilirubin no greater than 1.5 times normal - SGOT and alkaline phosphatase no greater than 3 times normal Renal: - Creatinine no greater than 1.5 mg/dL Other: - No significant infection - Not pregnant - Fertile patients must use effective contraception - No other invasive malignancy within the past 5 years except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent filgrastim (G-CSF) Chemotherapy: - No prior gemcitabine - At least 3 weeks since other prior chemotherapy for cervical cancer and recovered - No more than 1 prior chemotherapy regimen (single or combination cytotoxic therapy) Endocrine therapy: - Not specified Radiotherapy: - At least 3 weeks since prior radiotherapy for cervical cancer and recovered Surgery: - At least 3 weeks since prior surgery for cervical cancer and recovered Other: - No prior cancer treatment that would preclude study



Primary Contact:

Study Chair
Russell J. Schilder, MD
Fox Chase Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.